Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.

Tripathy D, Brufsky A, Cobleigh M, Jahanzeb M, Kaufman PA, Mason G, O'Shaughnessy J, Rugo HS, Swain SM, Yardley DA, Chu L, Li H, Antao V, Hurvitz SA.

Oncologist. 2019 Oct 14. pii: theoncologist.2019-0446. doi: 10.1634/theoncologist.2019-0446. [Epub ahead of print]

PMID:
31611330
2.

Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.

Sparano JA, Gray RJ, Makower DF, Albain KS, Saphner TJ, Badve SS, Wagner LI, Kaklamani VG, Keane MM, Gomez HL, Reddy PS, Goggins TF, Mayer IA, Toppmeyer DL, Brufsky AM, Goetz MP, Berenberg JL, Mahalcioiu C, Desbiens C, Hayes DF, Dees EC, Geyer CE Jr, Olson JA Jr, Wood WC, Lively T, Paik S, Ellis MJ, Abrams J, Sledge GW Jr.

JAMA Oncol. 2019 Sep 30. doi: 10.1001/jamaoncol.2019.4794. [Epub ahead of print]

PMID:
31566680
3.

CDK4/6 inhibitors: taking the place of chemotherapy?

Nasrazadani A, Brufsky AM.

Lancet Oncol. 2019 Oct;20(10):1329-1330. doi: 10.1016/S1470-2045(19)30507-8. Epub 2019 Sep 4. No abstract available.

PMID:
31494036
4.

Artificial intelligence-directed prognostication of breast cancer.

Nasrazadani A, Brufsky AM.

EBioMedicine. 2019 Aug;46:6-7. doi: 10.1016/j.ebiom.2019.07.073. Epub 2019 Aug 1. No abstract available.

5.

Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Brufsky A, Kennedy L, Bhatta S, Bhowmik D, Buchanan J, Despiegel N, Hechmati G.

J Med Econ. 2019 Aug 26:1-11. doi: 10.1080/13696998.2019.1651122. [Epub ahead of print]

PMID:
31364885
6.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
7.

Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2- Advanced Breast Cancer Enrolled in an Expanded Access Program.

Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearns V.

Clin Breast Cancer. 2019 Oct;19(5):317-325.e4. doi: 10.1016/j.clbc.2019.04.005. Epub 2019 Apr 18.

8.

Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.

Sambade MJ, Prince G, Deal AM, Trembath D, McKee M, Garrett A, Keith K, Ramirez J, Midkiff B, Blackwell K, Sammons S, Leone JP, Brufsky A, Morikawa A, Brogi E, Seidman A, Ewend M, Carey LA, Moschos SJ, Hamilton RL, Vincent B, Anders C.

Breast Cancer Res Treat. 2019 Jul;176(2):321-328. doi: 10.1007/s10549-019-05211-1. Epub 2019 Apr 23.

PMID:
31016641
9.

A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis.

Jiang X, Wells A, Brufsky A, Neapolitan R.

PLoS One. 2019 Mar 8;14(3):e0213292. doi: 10.1371/journal.pone.0213292. eCollection 2019.

10.

Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.

Klar N, Rosenzweig M, Diergaarde B, Brufsky A.

Clin Breast Cancer. 2019 Aug;19(4):304-310. doi: 10.1016/j.clbc.2019.01.014. Epub 2019 Feb 6.

PMID:
30827763
11.

Targeted mutation detection in breast cancer using MammaSeq™.

Smith NG, Gyanchandani R, Shah OS, Gurda GT, Lucas PC, Hartmaier RJ, Brufsky AM, Puhalla S, Bahreini A, Kota K, Wald AI, Nikiforov YE, Nikiforova MN, Oesterreich S, Lee AV.

Breast Cancer Res. 2019 Feb 8;21(1):22. doi: 10.1186/s13058-019-1102-7.

12.

Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy.

Han M, Salamat A, Zhu L, Zhang H, Clark BZ, Dabbs DJ, Carter GJ, Brufsky AM, Jankowitz RC, Puhalla SL, Johnson RR, Soran A, Steiman JG, McAuliffe PF, Diego EJ, Bhargava R.

Mod Pathol. 2019 Jun;32(6):807-816. doi: 10.1038/s41379-019-0208-x. Epub 2019 Feb 5.

PMID:
30723293
13.

Extended adjuvant therapy for early-stage breast cancer: Are there markers for its use?

Klar N, Brufsky A.

Breast J. 2019 Jan;25(1):7-8. doi: 10.1111/tbj.13038. No abstract available.

PMID:
30659735
14.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2019 Jul 1;30(7):1179. doi: 10.1093/annonc/mdy535. No abstract available.

PMID:
30624662
15.

Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs.

Hurvitz SA, O'Shaughnessy J, Mason G, Yardley DA, Jahanzeb M, Brufsky A, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M.

Clin Cancer Res. 2019 Apr 15;25(8):2433-2441. doi: 10.1158/1078-0432.CCR-18-2366. Epub 2018 Dec 28.

PMID:
30593513
16.

Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N.

Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30509771
17.

Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood.

Gyanchandani R, Kvam E, Heller R, Finehout E, Smith N, Kota K, Nelson JR, Griffin W, Puhalla S, Brufsky AM, Davidson NE, Lee AV.

Sci Rep. 2018 Nov 23;8(1):17313. doi: 10.1038/s41598-018-35470-9.

18.

Statin drugs to reduce breast cancer recurrence and mortality.

Beckwitt CH, Brufsky A, Oltvai ZN, Wells A.

Breast Cancer Res. 2018 Nov 20;20(1):144. doi: 10.1186/s13058-018-1066-z. Review.

19.

Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use.

Pandey A, Brufsky AM.

Clin Breast Cancer. 2019 Feb;19(1):e7-e11. doi: 10.1016/j.clbc.2018.09.010. Epub 2018 Oct 4. No abstract available.

PMID:
30391215
20.

Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues.

Heng YJ, Wang J, Ahearn TU, Brown SB, Zhang X, Ambrosone CB, de Andrade VP, Brufsky AM, Couch FJ, King TA, Modugno F, Vachon CM, DuPre NC, Garcia-Closas M, Troester MA, Hunter DJ, Eliassen AH, Tamimi RM, Hankinson SE, Beck AH.

Breast Cancer Res Treat. 2019 Feb;173(3):667-677. doi: 10.1007/s10549-018-5034-1. Epub 2018 Nov 1.

PMID:
30387004
21.

CACNG2 polymorphisms associate with chronic pain after mastectomy.

Bortsov AV, Devor M, Kaunisto MA, Kalso E, Brufsky A, Kehlet H, Aasvang E, Bittner R, Diatchenko L, Belfer I.

Pain. 2019 Mar;160(3):561-568. doi: 10.1097/j.pain.0000000000001432.

PMID:
30371558
22.

Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, Boisen MM, Bhargava R, Weiss KR, Karsten MM, Denkert C, Blohmer JU, Leone JP, Hamilton RL, Brufsky AM, Elishaev E, Lucas PC, Lee AV, Oesterreich S.

Mol Cancer Res. 2019 Feb;17(2):457-468. doi: 10.1158/1541-7786.MCR-18-0946. Epub 2018 Oct 24.

PMID:
30355675
23.

Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer.

Merriman JD, Sereika SM, Conley YP, Koleck TA, Zhu Y, Phillips ML, Bertocci MA, Brufsky AM, Bender CM.

Biol Res Nurs. 2019 Jan;21(1):50-60. doi: 10.1177/1099800418799964. Epub 2018 Sep 13.

PMID:
30213196
24.

Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.

Stearns V, Brufsky AM, Verma S, Cotter MJ, Lu DR, Dequen F, Joy AA.

Clin Breast Cancer. 2018 Dec;18(6):e1239-e1245. doi: 10.1016/j.clbc.2018.07.007. Epub 2018 Jul 30.

PMID:
30172722
25.

Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).

Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr.

J Clin Oncol. 2018 Sep 1;36(25):2621-2629. doi: 10.1200/JCO.2018.79.2028. Epub 2018 Jul 24.

26.

Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.

Varešlija D, Priedigkeit N, Fagan A, Purcell S, Cosgrove N, O'Halloran PJ, Ward E, Cocchiglia S, Hartmaier R, Castro CA, Zhu L, Tseng GC, Lucas PC, Puhalla SL, Brufsky AM, Hamilton RL, Mathew A, Leone JP, Basudan A, Hudson L, Dwyer R, Das S, O'Connor DP, Buckley PG, Farrell M, Hill ADK, Oesterreich S, Lee AV, Young LS.

J Natl Cancer Inst. 2019 Apr 1;111(4):388-398. doi: 10.1093/jnci/djy110.

27.

Pathologist's health-care value in the triage of Oncotype DX® testing: a value-based pathology study of tumour biology with outcomes.

Dabbs DJ, Clark BZ, Serdy K, Onisko A, Brufsky AM, Smalley S, Perkins S, Bhargava R.

Histopathology. 2018 Oct;73(4):692-700. doi: 10.1111/his.13690. Epub 2018 Aug 6.

PMID:
29920746
28.

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.

Yardley DA, Coleman R, Conte P, Cortes J, Brufsky A, Shtivelband M, Young R, Bengala C, Ali H, Eakel J, Schneeweiss A, de la Cruz-Merino L, Wilks S, O'Shaughnessy J, Glück S, Li H, Miller J, Barton D, Harbeck N; tnAcity investigators.

Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.

29.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

30.

Low Estrogen Receptor (ER)-Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy: Is Response Similar to Typical ER-Positive or ER-Negative Disease?

Landmann A, Farrugia DJ, Zhu L, Diego EJ, Johnson RR, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R.

Am J Clin Pathol. 2018 May 31;150(1):34-42. doi: 10.1093/ajcp/aqy028.

PMID:
29741562
31.

Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.

Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, Rosenzweig MQ, Brufsky AM, McAuliffe P, Zhu Y, Conley YP.

Oncol Nurs Forum. 2018 May 1;45(3):308-326. doi: 10.1188/18.ONF.308-326.

32.

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.

Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA.

J Clin Oncol. 2018 Jun 1;36(16):1556-1563. doi: 10.1200/JCO.2017.76.9331. Epub 2018 Apr 17.

PMID:
29664714
33.

Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer.

Clark BZ, Farrugia DJ, Landmann A, Diego EJ, Dabbs DJ, Puhalla SL, Jankowitz RC, Brufsky AM, Ahrendt GM, McAuliffe PF, Bhargava R.

Am J Clin Pathol. 2018 Mar 7;149(4):332-343. doi: 10.1093/ajcp/aqx168.

PMID:
29481634
34.

Effect of gastroretentive gabapentin (Gralise) on postmastectomy pain syndrome: a proof-of-principle open-label study.

Belfer I, Pollock NI, Martin JL, Lim KG, De La Cruz C, Van Londen G, Nunziato-Virga SR, Stranieri K, Brufsky AM, Wang H.

Pain Rep. 2017 Apr 11;2(3):e596. doi: 10.1097/PR9.0000000000000596. eCollection 2017 May.

35.

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.

Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali SM, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL, Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV.

Ann Oncol. 2018 Apr 1;29(4):872-880. doi: 10.1093/annonc/mdy025.

36.

Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.

Brufsky AM, Dickler MN.

Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19. Review.

37.

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2.

Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N.

J Clin Oncol. 2017 Dec 10;35(35):3942-3948. doi: 10.1200/JCO.2017.74.1165. Epub 2017 Oct 26.

38.

Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30.

Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162.

39.

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification.

Kota K, Brufsky A, Oesterreich S, Lee A.

Cureus. 2017 Jul 6;9(7):e1434. doi: 10.7759/cureus.1434.

40.

Alcohol consumption and breast tumor gene expression.

Wang J, Heng YJ, Eliassen AH, Tamimi RM, Hazra A, Carey VJ, Ambrosone CB, de Andrade VP, Brufsky A, Couch FJ, King TA, Modugno F, Vachon CM, Hunter DJ, Beck AH, Hankinson SE.

Breast Cancer Res. 2017 Sep 12;19(1):108. doi: 10.1186/s13058-017-0901-y.

41.

Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases.

Priedigkeit N, Watters RJ, Lucas PC, Basudan A, Bhargava R, Horne W, Kolls JK, Fang Z, Rosenzweig MQ, Brufsky AM, Weiss KR, Oesterreich S, Lee AV.

JCI Insight. 2017 Sep 7;2(17). pii: 95703. doi: 10.1172/jci.insight.95703. eCollection 2017 Sep 7.

42.

Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer.

Mathew A, Achkar T, Abberbock S, Sandhu GS, Jacob ME, Villgran VD, Rosenzweig MQ, Puhalla S, Brufsky AM.

Breast J. 2017 Nov;23(6):718-722. doi: 10.1111/tbj.12905. Epub 2017 Aug 28.

43.

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer.

Schroeder B, Zhang Y, Stål O, Fornander T, Brufsky A, Sgroi DC, Schnabel CA.

NPJ Breast Cancer. 2017 Aug 3;3:28. doi: 10.1038/s41523-017-0037-3. eCollection 2017.

44.

Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast.

Mathew A, Rajagopal PS, Villgran V, Sandhu GS, Jankowitz RC, Jacob M, Rosenzweig M, Oesterreich S, Brufsky A.

Geburtshilfe Frauenheilkd. 2017 Jun;77(6):660-666. doi: 10.1055/s-0043-109374. Epub 2017 Jun 28.

45.
46.

TACT2: improving treatment tolerability in early breast cancer.

Mathew A, Brufsky A.

Lancet Oncol. 2017 Jul;18(7):843-845. doi: 10.1016/S1470-2045(17)30437-0. No abstract available.

PMID:
28677561
47.

Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors.

Farrugia DJ, Landmann A, Zhu L, Diego EJ, Johnson RR, Bonaventura M, Soran A, Dabbs DJ, Clark BZ, Puhalla SL, Jankowitz RC, Brufsky AM, Lembersky BC, Ahrendt GM, McAuliffe PF, Bhargava R.

Mod Pathol. 2017 Aug;30(8):1078-1085. doi: 10.1038/modpathol.2017.41. Epub 2017 May 26.

48.

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.

Yardley DA, Arrowsmith ER, Daniel BR, Eakle J, Brufsky A, Drosick DR, Kudrik F, Bosserman LD, Keaton MR, Goble SA, Bubis JA, Priego VM, Pendergrass K, Manalo Y, Bury M, Gravenor DS, Rodriguez GI, Inhorn RC, Young RR, Harwin WN, Silver C, Hainsworth JD, Burris HA 3rd.

Breast Cancer Res Treat. 2017 Aug;164(3):649-658. doi: 10.1007/s10549-017-4285-6. Epub 2017 May 15.

PMID:
28508185
49.

An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.

Koleck TA, Bender CM, Clark BZ, Ryan CM, Ghotkar P, Brufsky A, McAuliffe PF, Rastogi P, Sereika SM, Conley YP.

Breast Cancer (Dove Med Press). 2017 Mar 3;9:95-110. doi: 10.2147/BCTT.S123785. eCollection 2017.

50.

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N.

J Clin Oncol. 2017 Aug 10;35(23):2647-2655. doi: 10.1200/JCO.2016.71.4147. Epub 2017 Apr 11.

Supplemental Content

Loading ...
Support Center